We describe a 68-year-old Japanese male with hypoplastic acute myelogenous leukemia (AML) who achieved complete hematological reconstitution following granulocyte colonystimulating factor (G-CSF) administration. The patient had pancytopenia and the bone marrow was hypocellular with 19 to 36%peroxidase-positive blasts without morphological abnormalities suggestive of myelodysplasia. After receiving G-CSFas a supportive therapy for pneumonia, the blood count became normal and the bone marrowwas normocellular with less than 5%of blasts. Without subsequent chemotherapy, he relapsed as a form of overt leukemia and died of pneumonia. Chemotherapy may be necessary to maintain remission in hypoplastic AMLafter hematopoietic reconstitution by G-CSF. (Internal Medicine 34: 692-694, 1995) 
Introduction
Hypoplastic acute myelogenous leukemia (AML)is a syndromethat includes pancytopenia and hypocellular marrow with an evident increase of leukemic blast cells in a proportion of 15-75% of marrow nucleated cells (1, 2) . This disease mainly affects the elderly and accounts for 5-7% of de novo AML (3) . The patients typically lack a preceding history of myelodysplasia.
Median survival without therapy is 6 to 9 months and most patients die of infectious episodes (2, 3) . Recently, the beneficial effects of hematopoietic growth factors have been reported in the treatment of hypoplastic AML(4-7). However, it remains unclear whether post remission chemotherapy is recommendedfor the patients whohave achieved remission by granulocyte colony-stimulating factor (G-CSF).
In this report, we describe a case with hypoplastic AMLwho achieved hematopoietic reconstitution after G-CSFinjection and discuss the pertinent literature.
Case Report
A 68-year-old Japanese male was referred to the hospital because ofpancytopenia on April ll, 1991. Days after the start of G-CSFtreatment Figure 1 . Hematological changes after G-CSF treatment. NCC: nucleated cell count, ANC:all nucleated cells.
injection ofG-CSFat a dose of 100 jig/day was started, and then the dose was escalated to 250 |ig/day. The patient did not receive concomitantadministration of anabolic steroids, other cytokines nor any other anti-tumor drugs. Within 2 weeks, the platelet count and Hbconcentration as well as granulocyte count began to increase synchronously and numerical criteria for complete remission was obtained 2 monthsafter the start of G-CSF injection (Fig. 1) . At that time, the bone marrow was normocellular with less than 5%of blasts. One month after the discontinuation of G-CSF, he relapsed as a form of overt leukemia. Bonemarrowaspirates showedhyperplastic marrow (more than 90% cellularity on a clot section) with 62% of blasts which were also positive for peroxidase reaction.
Immunophenotyping of marrow cells revealed that blasts were positive for CD13, CD33 and HLA-DR. Reinduction chemotherapy and G-CSFwas not successful. Six months after the relapse, he died of severe pulmonary infection. However, analyses of the clonality in hematopoietic tissues and assay for G-CSFreceptor on blast cells will be necessary to clarify the mechanisms by which G-CSFcontribute to the hematopoietic reconstitution in hypoplastic AML.
There have been only four reports describing successful remission induction with G-CSFadministration in patients with hypoplastic AML, known to date (4, 6, 7, 14) . The remission duration appears to be quite short in patients whowere not given cytotoxic agents after obtaining remission (Table 1 ; present case and cases 3 and 4). Onereported case maintained remission for more than 48 months with post remission chemotherapy. Intensive chemotherapy has been reported to be successful in some patients with hypoplastic leukemia (5, 15) . Chemotherapy may be feasible and reasonable in hypoplastic AML following the reconstitution of apparently normal hematopoiesis with G-CSF.
